Society guideline links: Gastroesophageal reflux in adults

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Barrett's esophagus" and "Society guideline links: Esophageal cancer" and "Society guideline links: Subacute and chronic cough in adults".)

International

●World Gastroenterology Organisation (WGO): Global guidelines on GERD – Global perspective on gastroesophageal reflux disease (2017)

Canada

●Choosing Wisely Canada: Don't maintain long term Proton Pump Inhibitor (PPI) therapy for gastrointestinal symptoms without an attempt to stop/reduce PPI at least once per year in most patients (2019)

●Canadian Association of Gastroenterology (CAG): Canadian consensus conference on the management of gastroesophageal reflux disease in adults, update (2004)

United States

●American College of Gastroenterology (ACG): Guidelines for the diagnosis and management of gastroesophageal reflux disease (2021)

●Society of American Gastrointestinal and Endoscopic Surgeons (SAGES): Guidelines for the surgical treatment of gastroesophageal reflux disease (GERD) (2021)

●American Gastroenterological Association (AGA): Clinical practice update – Expert review: Functional lumen imaging probe for the management of esophageal disorders (2017)

●AGA: Clinical practice update –Expert review and best practice advice on the risks and benefits of long-term use of proton pump inhibitors (2017)

●American Society of Gastrointestinal Endoscopy (ASGE): The role of endoscopy in the management of GERD (2015)

●Choosing Wisely: For pharmacological treatment of patients with gastroesophageal reflux disease (GERD), long-term acid suppression therapy (proton pump inhibitors or histamine2 receptor antagonists) should be titrated to the lowest effective dose needed to achieve therapeutic goals (2012)

●AGA: Medical position statement on the management of gastroesophageal reflux disease (2008)

Europe

●European Association of Endoscopic Surgery (EAES): Recommendations for the management of gastroesophageal reflux disease (2014)

United Kingdom

●National Institute for Health and Care Excellence (NICE): Clinical guideline on gastro-oesophageal reflux disease and dyspepsia in adults – Investigation and management (2014, updated 2019)

●NICE: Interventional procedures guidance on laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease (2017)

●NICE: Interventional procedures guidance on electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease (2015)

●NICE: Interventional procedures guidance on endoscopic radiofrequency ablation for gastro-oesophageal reflux disease (2013)

●NICE: Interventional procedures guidance on endoluminal gastroplication for gastro-oesophageal reflux disease (2011)

Australia-New Zealand

●Choosing Wisely Australia: Do not continue prescribing long term proton pump inhibitor (PPI) medication to patients without attempting to reduce the medication down to the lowest effective dose or cease the therapy altogether (2016)

●Choosing Wisely Australia: Don't use proton pump inhibitors (PPIs) long term in patients with uncomplicated disease without regular attempts at reducing dose or ceasing (2015)

Japan

●[In Japanese] Japanese Society of Gastroenterology (JSGE): Evidence-based clinical practice guidelines for GERD, 2nd edition (2015)